ADDICTION

Author Index, Volume 89, 1994

* Indicates a Book Reviewer
# Indicates News and Notes Contributor

Aasland, O. G., 674
Abraham, H. D., 763
Adan, A., 455
Adlaf, E. M., 1675
Ager, C. R., 1143
Aldridge, A. M., 763
Alim, T. N., 1097
Allison, J., 563
Almond, B., 296
Altshuler, V. B., 1069
Anderson, P., 35, 41, 49, 649, 668, 760, 1523
Andreatini, R., 1129
Andreski, P., 743
Andrew, T., 1299
Anstine, P. S., 699
Anthenelli, R., 1629
Apfelbaum, J. L., 831
Araya, R., 955
Arora, A., 1697
Ashton, H., 1535

Babor, T. F., 531, 657, 676, 1059, 1391
Baker, P. J., 484
Balfour, D. J. K., 1419
Ball, J. C., 263, 799, 813
Barnas, C., 1287
Barrett, D. C., 971
Barry, J., 603
Bastos, F. I., 689
Basu, D., 1697
Bell, J., 463
Bensley, L. S., 1265
Bera, N. K., 1017
Beresford, T. P., 1043
Bernard, M. A., 97
Berridge, V., 534
Bertolucci, D., 227
Bickel, W. K., 1461
Bieleman, B., 1517
Blane, H. T., 533
Bloor, M., 353
Blume, S. B., 526
Blume, S. M., 1177*
Blunden, S., 1319
Bond, A., 821
Boomsma, D. I., 219
Bozarth, M. A., 1425
Bradshaw, J., 563
Breslau, N., 743
Bucholz, K., 1629
Bühringer, G., 811, 1197

Caldwell, D., 765#
Calsyn, D. A., 191
Cameron, J., 97
Camí, J., 14, 619#, 1707#
Campbell, K. E., 413
Campion, P., 1245
Capelhorn, J. R. M., 203, 463
Carlini, E. A., 362#
Carr, S. V., 763
Casswell, S., 425, 762, 1258
Caulkins, J. P., 815
Celentanto, D. D., 1309
Chavan, B. S., 317
Cherpitel, C. J., 157
Chick, J., 664, 1613
Chou, S. P., 87
Chowdhury, A. N., 1017
Clements, K., 363#
Cluff, M. C., 203
Coalson, D. W., 831
Cohen, J., 1077, 1683
Cohn, S., 1309
Collins Jr., J. P., 1097
Connolly, G. M., 1258
Cook, C. C. H., 615*
Crosby, G. M., 971

Dalton, M. S. Y. N., 203
Darke, S., 211, 311, 379, 1077, 1683, 1703
Davidson, R., 18
Davila, R., 1135
Dawling, S., 821
Dawson, D. A., 345
Delaney, W., 183
Dépelteau, L., 1619
Des Jarlais, D. C., 383, 689, 807
Desmarais-Gervais, L., 1619
Deutsch, S. I., 1097
Diamond, J., 875
Dinwiddie, S. H., 925
Dobkin, P. L., 1619
Dole, V., 23
Donoghoe, M. C., 755, 1085
Dorman, A., 96
Doulds, A. C., 259
Doyle, H., 183
Duckert, F., 667
Duffy, S. W., 756

Eaton, G., 1601
Edwards, G., 9, 20, 102*, 553, 609, 617*, 1178*, 1227, 1293
Egelko, S., 1227
Elliott, L., 97
Engelhard, D., 869
Erin, C. A., 299
Evans, D., 295

Falk, M., 1287
Farrell, M., 355*, 812, 878*, 1471
Farren, C., 432
Farrow, K., 97
Fay-McCarthy, M., 1097
Fergusson, D. M., 1007, 1277
Fernö, O., 1215
Ferrer, H. P., 1143
Ferri, C. P., 1129
Feuerlein, W., 841
Fillmore, K. M., 1066, 1143
Finch, E., 812
Fitzpatrick, E., 603
Fleischhacker, W. W., 1287
Flemming, D., 831
Flohrschütz, T., 841
Formigoni, M. L. O. de S., 1129
Forster, J. L., 699

Foster, V., 831
Foulds, J., 136, 438
Fowler, G., 432, 482
Friedman, S. R., 689
Friedmann, P., 689
Frischer, M., 353, 763
Fromme, K., 63
Fukui, S., 331

Gabe, J., 1497
Galanter, M., 521, 1227
Galduróz, J. C. F., 1129
Gentil, V., 447
Gerada, C., 103*
Giffen, P. J., 1183*
Glaser, F. B., 921
Godfrey, C., 915, 923
Gold, J., 473
Goldberg, D. J., 353, 763
Golding, J. M., 1143
Goodliffe, J., 1237
Gossop, M., 301, 358*, 961, 1355, 1483
Gotoh, M., 953
Grant, B. F., 227, 573, 1357
Grant, M., 657
Green, S. T., 353, 763
Griffiths, P., 301, 961
Gruenewald, P. J., 707
Gruer, L., 97, 763
Grunberg, N. E., 1443
Gudjonsson, G. H., 985
Guenther, V., 1287
Guppy, A., 881*
Gurin, G., 581

Hajek, P., 1543
Hall, W., 79, 211, 311, 920, 1077
Hamilton, M., 151
Hammarström, A., 1691
Hammersley, R., 283
Hando, J., 79, 1077
Hanson, B. S., 707
Harford, T. C., 393, 421
Harrison, D., 1613
Harrison, S., 95
Hartgers, C., 102*
Hartnoll, R. L., 1377
Hasin, D. S., 573
Hawks, D., 351
Haworth, A., 355*, 652
Healey, C., 563
Heath, D. B., 523, 880*
Heather, N., 665
Hedrich, D., 356*
Hennessy, M., 1639
Henningfield, J. E., 135, 434
Hensley, M. J., 1319
Hesselbrock, V., 1629
Higgins, S. T., 1461
Hodgson, R., 1529
Holder, H. D., 919
Holman, R. B., 1435
Holme, I., 401
Horwood, L. J., 1007, 1277
Howard, G., 297
Huber, C., 513
Hughes, J. R., 1461
Hummer, M., 1287
Hunter, G. M., 755, 1085
Husch, J. A., 1517

Ikuesan, B. A., 654, 941
Irwin, M. R., 73, 441
Ivis, F. J., 1675

Jackson, T. R., 191
James, J. E., 1595
Janlert, U., 1691
Jarvis, M. J., 1371
Jeanfrançois, N., 1025#
Johns, A., 1551
Johnson, H., 603
Johnson, P. B., 581
Johnson, Z., 603
Johnstone, B. M., 1066
Jones, B. T., 1653

Kalant, H., 13
Kaplan, C. D., 357*, 1517
Katcher, B., 537
Keenan, E., 96
Kilbey, M. M., 743
King, M. B., 1367
Klee, H., 1181*
Klepp, K-I., 1157
Koopmans, J. R., 219
Kosten, T. R., 1477
Kristenson, H., 671
Kua, E. H., 956
Küfner, H., 841

Laberg, J. C., 1157
Labouvie, E. W., 1105, 1115
Lader, M., 821, 1413
Lago, J. A., 1477
Lang, E., 167
Langenbucher, J., 1105, 1115
Larsen, S., 733
Leigh, B., 131
Leino, E. V., 1066, 1143
Lemmens, P. H., 593, 1704
Levine, H. G., 535
Lichtor, J. L., 831
Lima, E. S., 689
Little, H., 1397
Littleton, J., 1397
Lockwood, D., 613*
Lotufo-Neto, F., 447
Lowenfels, A. B., 1021
Lucey, M. R., 1043
Lunnay, D., 1319
Lynskey, M. T., 1007, 1277

Maayan, S., 869
Madden, J. S., 763
Malhotra, A., 1697
Mann, K., 5
Marks, I., 1179*
Marshall, E. J., 1293
Marshall, M., 648
Mattoo, S. K., 1697
Maxwell, J. D., 259
McCann, U. D., 539
McDermott, I., 791
McGovern, P. G., 699
McGrath, D., 167
McGuire, C., 1245
McKeganey, N., 353
McMahon, J., 1653
McMahon, R., 1265
McNeil, D. R., 463
McNeill, A., 1245, 1505
Medina-Mora, E., 959
Michelin, L., 1709#
Midanik, L. T., 393, 407, 971
Milby, J. B., 100*
Moore, D., 16
Moos, R. H., 31, 507
Morgenstern, J., 1105, 1115
Motoyoshi, M., 1143
Mphi, M., 945
Mulford, H. A., 517, 527
Mullen, K., 766#
Muñoz, A., 1309
Murashima, Y. L., 587
Muthuen, B., 573

Najavits, L. M., 679
Nathan, P. E., 1115
Nelson, K. E., 1309
Nephew, T., 707
Nigam, A. K., 317
Nordland, S., 401

O'Brien, C. P., 1565
O'Connor, M., 603
O'Connor, J. J., 96
Oberbauer, H., 1287
Odd, R., 431
Olsen, G. W., 1167
Oppenheimer, E., 1299
Orlebek, J. F., 219
Österberg, E., 522
Österling, A., 671
Owen, L., 1245

Pacurucu-Castillo, S., 238#, 951, 1708#
Parker, R. N., 1639
Parrott, A., 142
Paul, J. P., 971
Perkins, J. J., 1319
Perry, C. L., 699
Petrenas, A-M., 203
Pétursson, H., 1455
Phyu, T. T., 1021
Pickering, H., 1385
Pomerleau, C. S., 321
Pomerleau, O. F., 321
Pomeroy, L., 603
Power, R., 1601
Powis, B., 301, 961
Pritchard, W. S., 481
Proudfit, A. H., 413
Pycha, R., 1287

Quinn, E. A., 413

Radziminski, S., 1629
Raistrick, D., 563, 1211
Ranganathan, S., 1071
Raw, M., 3, 1505
Redman, S., 1319
Reinarman, C., 535
Reuter, P., 806
Reynolds, A., 877*
Rezza, G., 809
Rhodes, T., 1085, 1601
Ricaurte, G. A., 539
Richmond, R. L., 35, 41, 49, 139, 662
Risser, D., 851
Ritson, B., 1491
Robinson, J. H., 481
Roman, P. M., 524
Ross, J., 1077, 1683
Ross, M., 311
Ross, M. W., 473
Rosse, R. B., 1097
Rossow, I., 999, 1667
Ruela, A., 63

Saltz, R. F., 1639
Samarasinghe, D., 643, 654
Sanchez-Craig, M., 660, 1135
Sanson-Fisher, R. W., 1319
Saxena, S., 317, 647, 883#
Saxon, A. J., 191
Schneider, B., 851
Schuckit, M. A., 73, 441, 1559, 1629
Scully, M., 603
Seijas, D., 821
Seivewright, N., 805, 1701
Sharples, L. D., 756
Sher, K. J., 1061
Sherman, D. I. N., 235
Shinba, T., 587
Shouval, D., 869
Shufman, E. N., 869
Sigurdsson, J. F., 985
Silagy, C., 482
Silva, P. A., 1258
Single, E., 361#, 395
Sitharthan, T., 167
Smart, R. G., 101*, 1675
Smith, G. T., 267
Smith, T. L., 73, 441
Smythe, B., 96
Sobell, L. C., 483
Sobell, M. B., 483
Sokou, K., 616*
Soteri, A., 1085
Speiglman, R., 859
Spieker, S. J., 1265
Spilich, G. J., 141
Spivak, K., 1135
Srivastava, R. P., 317
Stall, R. D., 131, 971
Steele, T. D., 539
Steinman, J., 761
Stephens, R. C., 614*
Stimson, G. V., 1085, 1385, 1601
Stinson, F. S., 227
Stockwell, T., 99*, 167, 1447, 1703
Stowe, A., 473
Strang, J., 301, 812, 961, 1511
Stuppaeck, C. H., 1287
Sundaram, K. R., 317
Sutton, S., 486#
Swift, W., 211, 311

Tamsfoss, S., 401
Tate, J. C., 321
Taylor, A., 763
Taylor, C., 553, 609, 1293, 1299
Tejero, A., 879*
Telles, P. R., 689
Tempesta, E., 878*
Tipp, J., 1629
Tober, G., 563
Tobin, J., 183
Tobutt, C., 1299
Torrens, M., 619#, 1178*, 1707#
Toumbourou, J., 151
Traeen, B., 999
Tremblay, R. E., 1619
Tsuang, J. W., 73
Tuyns, A. J., 1021

Uchtenhagen, A., 1180*

Vaillant, G. E., 1049, 1069
Van de Winjngaart, G. F., 799
Van Den Brink, W., 102*
Van Doornen, L. J. P., 219
Varma, V. K., 1064, 1697
Vergaray, M., 1227
Vlahov, D., 1309

Wada, K., 331
Wagenaar, A. C., 699
Walsh, G. W., 1675
Warburton, D. M., 138
Ward, T. P., 689
Weiner, J., 563
Weiss, R. D., 679
Weiss, S., 352
Wells, B., 806
West, R., 144, 436, 482, 1355, 1483
Whitworth, A., 1287

Widiger, T. A., 267
Wilhelmsen, B. U., 1157
Williams, G. D., 413
Williams, R., 235
Windle, M., 167
Wisnicki, K. S., 573
Wodak, A., 147, 473, 614*, 787, 803
Wolfson, M., 699
Woodhouse, K., 432
Wortley, S., 393
Wyllie, A., 425
Yamamoto, K-I., 587
Zacny, J. P., 831
Zhang, J-F., 425, 1258
Zobeck, T. S., 227

ADDICTION

Subject Index, Volume 89, 1994

The following abbreviations have been used in this index:
Ed Editorial
L Letter
* Book review
# News and Notes

Aborigines, substance use, 1319–1332
Addiction
  behavioural ecomomics, 363–364#
  combined treatment with psychiatric disorders, 1227–1236
  comparison of disorders, 1355–1569
    biological processes, 1397–1446
    prevalence and demographic factors, 1357–1396
    prevention, 1491–1527
    treatment, 1529–1569
    withdrawal syndrome, 1447–1489
  conferences, 100*, 357*, 1180*
  DSM-IV dependence criteria across substances, 1105–1113
  factors in recovery, 507–509(Ed)
  memory in research, 283–293
  and reductionism, 9–12(Ed), 13–22
  services, cost-effectiveness, 915–917(Ed), 919–923
Addiction
  authors' instructions, 3–4(Ed), 1333#
  referees, 117–119
  unexpected text, vol. 88 p.1690, 240
Addiction Abstracts, 511(Ed)
Adolescents
  drinking
    childhood exposure to alcohol, 1007–1016
    mass media portrayal, 1255–1264
  drugs
    and delinquency, 1675–1681
    ecstasy use in Spain, 619–620#
  risk behaviours, 175–182
  smoking in Japan, 331–343
  see also Young people
Advertising
  and alcohol, 886–887#, 1255–1264
  and tobacco, 765#
Advisory Council on the Misuse of Drugs report, 1211–1214(Ed)
Africa, alcohol and drinking, 355*, 941–944, 945–949, 951–960
AIDS/HIV infection, 614*
  drug injectors
    cross-national studies, 383–392
    explanations for sharing equipment, 473–479
    frontloading, 755–756(L)
    India, 885–886#
    longitudinal changes, 191–202
    needle/syringe exchange, 102*, 603–607
    outreach programmes, 1601–1611
    risk behaviour, 79–85, 191–202, 473–479, 603–607, 689–698, 755–756(L), 1309–1318
    sexual behaviour, 131–134(Ed), 971–983, 1085–1096
    Spain, 1707–1708#
    UK, current issues, 1211–1214(Ed)
    women and social care, 356*
  research, 1199#
  sexual risks by gay addicts, 971–983
Alcohol
  and advertising
    India, 886–887#
    recall by adolescents, 1255–1264
  consumption
    adolescents, 1255–1264
    Africa, 355*
    and availability, 105#, 699–705
    beverage labels, 1639–1651
    brief interventions, 35–40, 41–47, 49–62, 486#, 657–678, 1135–1142
    chronotype and personality factors, 455–462
    controlled drinking, 483–484(L)
    and crime, 107#, 613*
    and driving *see* Drink-driving

emergency room studies, 157–165
Europe, 787–789(Ed)
expectancies and negative affect, 581–586
GPs' advice, 35–40, 41–47, 49–62
by hotel/restaurant staff, 733–741
India, 884–885#
as indicators of dependence, 345–350
Italy, 1709–1710#
Kenya, 355*
measurement, 393–430, 593–601, 1703–1706(L)
moderation, 99#, 235(L), 237–238#, 351(L), 761–762(L)
mortality, 756–761(L), 1293–1298
Norway, 999–1006
in pregnancy, 103*. 1021–1023(L)
problems *see* Alcohol problems
self reports, 395–399, 593–601, 1703–1706(L)
in the service industry, 733–741
sexual risks behaviour, 131–134(Ed)
standard measures, 593–601, 1703–1706(L)
and suspects' confessions to police, 985–997
Sweden, 725–732
UK licensing laws, 105#
US *see* United States
and violence, 157–165
women *see* Women and alcohol
young people, 63–71, 699–705
dependence, 1397–1412
DSM-III-R, 1129–1134
DSM-IV, 1105–1113, 1115–1127, 1357–1365
gender differences in morbidity, 87–93
validity of bi-axial concept, 575–579
see also Alcoholism
education, school-based, 1157–1167
expectancies, 1653–1665
fetal alcohol syndrome, 103*, 880*, 1021–1023(L)
industry
Ecuador, 238–239#
Europe, 787–789(Ed)
policies
Canada, 361–362#
developing countries, 355*, 643–646(Ed), 647–656
Europe, 1333#
Germany, 1198#
prevention, 1491–1496
and protective effect debate, 761–762(L)
problems
cross-national study, 657–678
dose-risk relationship, 756–761(L), 1143–1156
heart, 259–261(Ed)
post-Prohibition knowledge, 531–538
prevention, 1491–1496
WHO brief interventions study, 657–678
questionnaires, 167–174, 563–572
research
consumption measurement, 393–430
comparison of measures, 425–430
effects of question order, 421–424
quantity/frequency variations, 413–420
quantity/frequency vs graduated frequency, 407–412
randomized response techniques, 401–405
self-reports, 395–399
controlled drinking, 483–484(L)
drinking patterns, 1357–1365
history, 531–538, 1167–1176, 1183*
mass media and adolescent drinking, 1255–1264
matching clients to treatment, 553–561, 609–611, 1529–1534
meta-analysis of consumption and problems, 1143–1156
modelling drinking patterns, 707–723
objectives, 1397–1412
withdrawal, 1447–1453
withdrawal, 1447–1453, 1461–1470
Alcoholic hallucinosis, characteristics of patients, 73–78
Alcoholism, 1397–1412
and African women, 941–944, 945–949, 951–960
and alcoholic hallucinosis, 73–78
biological processes, 1397–1412
children of alcoholics *see* Children of alcoholics
and depression, 441–445
disciplinary proceedings for lawyers, 1237–1244
and the family, 615*, 1049–1057, 1059–1070
gender differences in morbidity, 87–93
among immigrants to Israel, 352–353(L)
insomnia and alcohol intake, 587–591
liver transplants, 1043–1048(Ed)
in the medical profession, 1613–1617
mortality, 20-year follow up, 1293–1298
and phobic anxiety, 447–453

screening by consumption indicators, 345–350
treatment, 5–7(Ed), 1529–1534
alcohol expectancies and relapse, 1653–1665
camps in rural India, 1071–1075
cost-effectiveness, 915–917(Ed), 919–923
Disulfiram, 878*
dually with psychiatric disorders, 1227–1236
follow-up of young attenders, 183–189
Honduras, 1708–1709#
matching patients to treatment, 553–561, 609–611, 1529–1534
mortality of treated clients, 841–849
outcome predictions, 31–34
resource allocation, 147–150
self-help, 99*, 1179*
therapist effectiveness, 679–688
types 1 and 2, 1049–1057, 1059–1070, 1397–1412
US *see* United States
WHO study of brief interventions, 657–678
withdrawal syndrome, 1287–1292, 1447–1453, 1461–1470
women, *see* Women and alcohol
Amphetamine abuse
and benzodiazepine use, 1683–1690
biological effects, 1435–1441
transitions in route of use, 1077–1083
withdrawal symptoms, 1477–1481
Australia
aboriginal substance use, 1319–1332
addiction in Victoria, 767#
benzodiazepine use, 1683–1690
drug and alcohol problems, 357*
GPs' advice, 35–40, 41–47, 49–62
methadone treatment, 95–96(L)
risk behaviour of amphetamine users, 79–85
self-help drug treatment, 151–156
WHO alcohol problems study, 657–678
Austria, drug-related deaths, 851–857

Barcelona, cocaine abuse, 878*
Benzodiazepine use
biological processes in dependence, 1413–1418
by amphetamine users, 1683–1690
by injecting drug users, 379–382(Ed), 1701–1703(L)
long-term users, 1367–1370
snorted flunitrazepam effects, 821–830
treatment, 1535–1541
withdrawal strategies, 1497–1504
withdrawal syndrome, 1455–1459, 1461–1470
Bolivia, 1335–1336#
Brazil
HIV among drug injectors, 689–698
trihexyphenidyl abuse, 362–363#
Bulgaria, WHO alcohol problems study, 657–678
Buprenorphine, naloxone-induced withdrawal, 317–320
Burma *see* Myanmar

Caffeine
factors in daily consumption, 455–462
health and commercial interests, 1595–1599(Ed)
see also Stimulants
California
drink-driving, 859–868, 1639–1651
drinking patterns, 707–723
Canada
addiction data, 1199#
alcohol
consumption, 395–399
history, 1183*
cigarette smuggling, 237#
drug/alcohol/tobacco policies, 361–362#
see also Ontario
Cancers and alcohol consumption, 756–761(L)
Cannabis
dependence and DSM-IV criteria, 1105–1113, 1115–1127
smoking and Koro, 1017–1020
Children
exposure to alcohol and drinking, 1007–1016
with fetal alcohol syndrome, 103*, 1021–1023(L), 880*
preventive smoking, 884#
school-based alcohol education, 1157–1167
Children of alcoholics, 355*
adolescent psychiatric disorders, 1277–1286
parenting behaviour, 1265–1276
physical health, 1619–1627
see also Adolescents
China, women and drinking problems, 951–960
Cigarettes *see* Smoking
Cirrhosis of liver *see* Liver cirrhosis
Clinical Institute Withdrawal Assessment —Alcohol, 1287–1292

Cocaine abuse
average prices, 815–819
dependence and DSM-IV criteria, 1105–1113, 1115–1127
effects, 877*, 1435–1441
Europe, 878*
paranoia and compulsive foraging, 1097–1104
prevalence data, 1385–1389
withdrawal symptoms, 1477–1481
Collaborative Alcohol-related Longitudinal project, 1143–1156
Costa Rica, WHO alcohol problems study, 657–678
Crime
and alcohol, 107#, 613*
and drugs, 614*, 1675–1681

Developing countries, alcohol policies, 355*, 643–646(Ed), 647–656, 1021(L)
Disulfiram applications, 878*
Doctors
drug abuse training in India, 887#
trends in alcoholism, 1613–1617
Dole, Vincent, interview, 23–29
Drink-driving, 485#, 881*
accidents
sentencing policies, 859–868
US, 227–233, 859–868
warnings on beverage containers, 1639–1651
Drugs
misuse, 1178*
Austria, 851–857
average prices, 815–819
biological processes, 1425–1434
diagnostic concepts of DSM, 267–282
DSM-IV dependence criteria, 1105–1113, 1115–1127
gay addicts, 971–983
Glasgow, 353(L), 763–764(L)
history, 102*, 875(L)
injectors
of benzodiazepines, 379–382(L), 1701–1703(L)
pseudoaneurysm, 1697–1699
injectors and AIDS/HIV
cross-national studies, 383–392
estimating prevalence, 353(L)
explanations for sharing equipment, 473–479
frontloading, 755–756(L)
India, 885–886#
needle sharing, 96–98(L)
needle/syringe exchange, 102*
outreach programmes, 1601–1611
risk behaviour, 79–85, 191–202, 473–479, 603–607, 689–698, 755–756(L), 1085–1096, 1309–1318
UK issues, 1211–1214(Ed)
Jerusalem, 869–874
prevalence and demographic factors, 1377–1383
prostitution and drug taking, 961–970
and psychiatric disorders, 1227–1236
questionnaires, 563–572
and sexual risk behaviour *see* Sexual behaviour
snorting, 821–830
and suicide, 1667–1673
and suspects' confessions to police, 985–997
US *see* United States, drugs
WHO report, 1198#
women *see* Women, drugs
Zürich, 513–516
policies
Canada, 361–362#
France, 1025–1027#
harm reduction, 1180*
prevention priorities, 1511–1516
UK, 1211–1214(Ed), 1497–1504
reinforcement processes, 1425–1434
research, 1425–1434
prevention priorities, 1511–1516
testing by hair analysis, 295–300
treatment, 879*, 1551–1558
cost effectiveness, 915–917(Ed), 919–923
dually with psychiatric disorders, 1227–1236
family systems therapy, 1178*
Germany, 1197–1198#
matching patients to treatment, 263–265, 799–802, 803–814
methadone *see* Methadone maintenance
resource allocation, 147–150
self-help vs harm reduction, 151–156
therapist effectiveness, 679–688
withdrawal syndrome, 1471–1475
see also specific drugs
Drunkenness habitual *see* Alcoholism
DSM-III-R
alcohol dependence criteria, 1129–1134
diagnostic concepts of abuse and dependence, 267–282
diagnostic criteria for substance use disorders, 1629–1638

nicotine dependence in young adults, 743–754
DSM-IV
dependence criteria across substances, 1105–1113
diagnostic concepts of abuse and dependencies, 267–282
diagnostic criteria for substance use disorders, 1629–1638
reliability of lifetime dependence diagnosis, 1115–1127
Dublin, HIV and risk behaviour in drug injectors, 603–607
Duckett, Henry, obituary, 897–898

Ecstasy
pharmacology and toxicology, 539–551
use in Spain, 619–620*
Ecuador, alcohol industry, 238–239#
Education and training of Indian doctors in substance abuse, 887#
Emergency room studies, 157–165, 763–764(L)
Employment
alcohol, depression and disciplinary proceedings, 1237–1244
in the tobacco industry, 1334–1335#
Ethanol *see* Alcohol
ETOH database updated, 766–767#
Europe
alcohol industry, 787–789(Ed)
cocaine abuse, 878*
prevalence of drug use, 1377–1383
tobacco advertising, 765#
WHO alcohol action plan, 1333#

Fernö, Ove, interview, 1215–1226
Flunitrazepam snorting effects, 821–830
France
drug policies, 1025–1027#
lead in wine, 1336#
Fraud in medical research, 358*

General practitioners, brief interventions, 35–40, 41–47, 49–62
Genetic factors in smoking, 219–226
Germany
alcohol withdrawal assessment, German version, 1287–1292
alcoholism treatment, 5–7(Ed)
news, 1197–1198#
Glasgow
drug injecting, 353(L)
siting of emergency services nearby, 763–764(L)
Glue sniffing *see* Volatile substance abuse
Great Britain *see* United Kingdom

Hair analysis for drugs, 295–300
Hallucinogens, dependence and DSM-IV criteria, 1105–1113
Health Education *see* Public health education
Heroin
addicts' risk of death, 203–209
average prices, 815–819
mortality among addicts, 1299–1308
patterns of administration, 301–309
prevalence and profile of use, 1377–1383
withdrawal symptoms, 1461–1470
see also Methadone maintenance
HIV infection *see* AIDS/HIV infection
Holland *see* Netherlands
Honduras alcoholism services, 1708–1709#

ICD-IO, diagnostic criteria for substance disorders, 1629–1638
India
alcohol treatment camps, 1071–1075
news, 883–887#
pseudoaneurysm in drug injecting users, 1697–1699
Inhalants abuse *see* Volatile substance abuse
Interviews
Vincent Dole, 23–29
Ignatius McDermott, 791–797
Ove Fernö, 1215–1226
Ireland, HIV and risks by drug injectors, 603–607
Israel
alcoholism in immigrants, 352–353(L)
drug use and hepatitis, 869–874
Italy
and alcohol, 1709–1710#
cigarette smuggling, 620#
cocaine abuse, 878*

Japan
adolescent smoking, 331–343
alcoholics and insomnia, 587–591
women and drinking problems, 951–960
Jersualem, drug users and hepatitis, 869–874

Kenya
alcohol and drinking, 355*
WHO alcohol problems study, 657–678

Kettil Bruun Society meeting, 393–430
Koro following cannabis smoking, 1017–1020

Legal issues
  alcohol, depression and disciplinary proceedings, 1237–1244
  tobacco litigation, 1334#
Lesotho, female alcoholism, 945–949, 951–960
Liver
  cirrhosis and alcohol consumption, 235(L), 351(L)
  transplants in alcoholics, 1043–1048(Ed)
LSD abuse epidemiology, 762–763(L)
Lysergic acid diethylamide *see* LSD

Mass media campaign on smoking and pregnancy, 1245–1254
McDermott, Msgr Ignatius, interview, 791–797
MDMA *see* Ecstasy
Methadone maintenance
  Dutch addicts' view, 799–802, 803–814
  Germany, 1197–1198#
  harm reduction vs rehabilitation, 799–802, 803–814
  intake procedure and outcome, 463–471
  prediction of risk behaviours, 311–316
  psychopathology among clients, 211–217
  retention and risk of death, 203–209
  Spain, 1707–1708#
  Victoria, Australia, 95–95(L)
  Vincent Dole interview, 23–29
Mexico
  WHO alcohol problems study, 657–678
  women and drinking problems, 951–960
Myanmar, women and drinking, 1021(L)

Needle park, Zürich, 513–516
Nepal, students and drugs, 101*
Netherlands
  addict's view of methadone maintenance, 799–802, 803–814
  cocaine abuse, 878*
New Zealand, alcohol consumption, 425–430.
Nicotine
  beneficial effects, 135–146, 481–482(L), 484(L)
  chronotype and personality factors in consumption, 455–462
  dependence, 1333#
    neural mechanisms, 1419–1423
    and psychiatric disorders, 743–754
    withdrawal syndrome, 1461–1470
  replacement treatments, 431–439, 884#, 1215–1226
Nigeria, women and drinking problems, 941–944, 951–960
Nitrous oxide inhalation effects, 831–839
Norway
  alcohol use in the service industry, 733–741
  characteristics of café visitors, 999–1006
  purchase of smuggled liquor, 401–405
  suicide among drug addicts, 1667–1673
  WHO alcohol problems study, 657–678

Obituary, Henry Duckett, 897–898
Okey memorial lecture, 383–392
Ontario, drug use, 1336#, 1675–1681
Opiates *see* Drugs *and specific opiates*
Ottawa Charter for health promotion, 1523–1527

Petrol sniffing *see* Volatile substance abuse
Physicians *see* Doctors *and* General practitioners
Prisoners
  confessions and alcohol/drug intoxication, 985–997
  HIV and condoms, 886#
Problem drinking *see* Alcoholism
Prostitution and drug taking, 961–970
Pseudoaneurysm in injecting drug use, 1697–1699
Psychiatric disorders
  in alcoholics, 441–445
  in children of alcoholics, 1277–1286
  combined treatment with addiction, 1227–1236
  in methadone maintenance clients, 211–217
Psychotherapist effectiveness in treatment, 679–688
Public health education
  GPs' interventions, 35–40, 41–47, 49–62, 657–678
  India, 884#
  mass media campaigns on smoking and pregnancy, 1245–1254
  Ottawa Charter, 1523–1527
  perceived risk by smokers, 486–487#
  prevention approaches, 1497–1504, 1523–1527
  sensible drinking, 235(L), 237–238#, 351(L)
Puerto Rico, negative affect and drinking, 581–586

Questionnaires
Confessions Questionnaire and prisoners, 985–997
Leeds Dependence Questionnaire, 563–572
Negative alcohol expectancy, 1653–1665
Severity of Alcohol Dependence in community samples, 167–174

Research in addictions
biological processes, 1443–1446
demography and epidemiology, 1391–1396
preventative strategies, 1523–1527
treatment approaches, 1565–1569
withdrawal syndrome, 1483–1489
see also Alcohol research *and* Drugs research
Research methods
average prices of drugs, 815–819
brief interventions, 41–47, 657–678
cost-effectiveness of services, 915–917(Ed), 919–923
fraud and misconduct, 358*
longitudinal alcohol research, 1357–1365
measurements issues, 393–430
modelling drinking patterns, 707–723
self-reports and memory, 283–293
Rio de Janeiro, HIV among drug injectors, 689–698
Risk behaviour
of drug injectors, 79–85, 131–134(Ed), 191–202, 311–316, 473–479, 603–607, 689–698, 755–756(L), 1085–1096, 1309–1318
of gay addicts, 971–983
Road accidents, alcohol-related *see* Drink-driving
Rotterdam, cocaine abuse, 878*

Scientific fraud, 358*
Scotland, alcoholism in doctors, 1613–1617
Sedatives, dependence and DSM-IV criteria, 1105–1113
Sexual behaviour
and AIDS/HIV, 79–85, 131–134(Ed), 191–202, 603–607, 689–698, 971–983, 1085–1096
and drug taking prostitutes, 961–970
Smoking
adolescents, 331–343
advertising and cigarettes, 765#
brief interventions by GPs, 35–40, 41–47, 49–62
cessation
Collaborative registry of trials, 482–483(L)
conference report, 765#
monitoring systems, 620–621#
in pregnancy, 1245–1254
treatment options, 1543–1549
genetic/social factors on starting, 219–226
motives, 321–330
perceived risks by smokers, 486–487#
prevalence and demographic factors, 1371–1376
preventing children starting, 884#
smoke-free zones, 239#
and unemployment, 1691–1696
and women, 616*
see also Nicotine *and* Tobacco
Smuggling of legal drugs, 237#, 620#
Solvent abuse *see* Volatile substance abuse
Spain
cocaine abuse, 878*
ecstasy use, 619–620#
HIV and methadone treatment, 1707–1708#
Soviet Union, WHO alcohol problems study, 657–678
Stimulants consumption
biological effects, 1435–1441
chronotype and personality factors, 455–462
dependence and DSM-IV criteria, 1105–1113
prevalence and demographic factors, 1385–1389
prevention strategies, 1517–1521
treatment for dependence, 1559–1563
withdrawal symptoms, 1461–1470, 1477–1481
see also Amphetamines
Street children and substance abuse, 106–107#, 362–363#
Suicide among drug addicts, 1667–1673
Sweden
Ove Fernö interview, 1215–1226
social networks and heavy drinking, 725–732
Tobacco control act, 363#, 1335#
Switzerland, Needle Park, Zürich, 513–516

Therapist effectiveness in treatment, 679–688
Tobacco
dependence *see* Nicotine addiction
history, 617*
industry and job creation, 1334–1335*
litigation, 1334#
public health policies, 1505–1509
Canada, 361–362#
Europe, 765#
India, 883–887#

Sweden, 363#, 1335#
UK, 239#
world conference, 1335#
see also Nicotine *and* Smoking
Traffic accidents, alcohol-related *see* Drink-driving
Training *see* Education and training
Trihexyphenidyl abuse, 363–363#
Turin, cocaine abuse, 878*

United Kingdom
alcohol
lawyer disciplinary proceedings, 1237–1244
licensing laws, 105#
Temperance and medical opinion, 1167–1176
WHO alcohol problems study, 657–678
drugs
outreach programmes, 1601–1611
policies, 1211–1214(Ed), 1497–1504
syringe exchange, 102*
GPs' advice, 35–40, 41–47, 49–62
tobacco litigation, 1334#
see also Scotland
United States
alcohol, 517–520, 521–529
availability, 699–705
consumption, 345–350, 407–424, 707–723, 1357–1365
drink-driving sentencing, 859–868
lawyer disciplinary proceedings, 1237–1244
liver transplants, 1043–1048(Ed)
post-Prohibition knowledge, 531–538
and traffic accidents, 227–233
WHO alcohol problems study, 657–678
combined psychiatric/addiction treatment, 1227–1236
drugs
average prices, 815–819
methadone maintenance, 799–802, 803–814
prevalence data, 1377–1383
McDermott, Ignatius interview, 791–797
risk behaviour in adolescents, 175–182
tobacco litigation, 1334#

Victoria, Australia, addiction, 767#
Violence
and alcohol, 157–165
and substance abuse, 614*, 1675–1681
Volatile substances abuse, 925–939
nitrous oxide effects, 831–839

Women
alcohol, 1177*
drinking patterns, 345–350
fetal alcohol syndrome, 103*, 1021–1023(L)
gender differences in morbidity, 87–93
Lesotho, 945–949, 951–960
Nigeria, 941–944, 951–960
Myanmar, 1021(L)
drugs, 1177*, 1181*
abuse by prostitutes, 961–970
needle-sharing patterns, 96–98(L)
and social care, 356*
and smoking, 616*, 1177*, 1245–1254
World Health Organization reports
brief interventions for alcohol problems, 657–678
drug dependence, 1198#
European alcohol action, 1333#
street children and substance abuse, 106–107#

Young people
alcohol consumption, 63–71
and availability, 699–705
and crime, 613*
follow-up of alcohol patients, 183–189
inhalants abuse, 925–939
nicotine dependence, 743–754
smoking and unemployment, 1691–1696
see also Adolescents

Zimbabwe, WHO alcohol problems study, 657–678
Zürich, Needle Park, 513–516